FDA recall, , Moderate risk
Northwest Compounders Semaglutide-Glycine-Cyanocobalamin Injectable
Semaglutide-Glycine-Cyanocobalamin Injectable lacks assurance of sterility.
Summary by Recall Canary from the FDA notice
What happened
PAYLESS COMPOUNDERS, LLC of Beaverton, Oregon recalled 91 vials of Semaglutide-Glycine-Cyanocobalamin Injectable, 2.5 mg, 5 mg, 1 MG/ML, 0.5 mL vials, Rx only, due to lack of assurance of sterility. The recall began March 6, 2026, and was added to the FDA's Enforcement Report on April 13, 2026, affecting Oregon.
What to do
We don't have product-specific instructions for this recall. FDA's general advice for medicine recalls:
- Check the FDA or company notice for instructions specific to this product.
- Ask your pharmacist or doctor whether your lot is affected and what to do.
Is yours affected?
Affected if its lot code is listed.
Semaglutide-Glycine-Cyanocobalamin Injectable
- Strength
- 2.5 mg
- Lot code
- 01-27-2026
- 14S.5
Recall details
- Company began the recall
- Sold in
- Company
- PAYLESS COMPOUNDERS, LLCBeaverton, Oregon
- Hazard
- Sterility problem
- Risk
Moderate risk
Taking it may cause short-term health problems, or ones that treatment can reverse. Serious harm is unlikely.
FDA Class II recall · How risk is rated
- Event ID
- 98646
- Recall number
- D-0471-2026
- Quantity recalled
- 91 vials
Timeline
FDA's Enforcement Report is its public list of recalls; FDA adds a recall when it posts it and publishes the list weekly.
Company began the recall
Added to FDA's Enforcement Report · Classified by FDA
In FDA's weekly enforcement report
Listed on Recall Canary
Summary updated
